Deutsche Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

Deutsche Bank’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,200	Closed	-$753K	–	3593
2024 Q4	$753K	Buy	+3,200	New	+$842K	﹤0.01%	2396
2024 Q3	–	Sell	-50,200	Closed	-$12.2M	–	3605
2024 Q2	$12.2M	Buy	50,200 +33,200	+195%	+$5.24M	0.01%	944
2024 Q1	$2.54M	Sell	17,000 -800	-4%	-$133K	﹤0.01%	1549
2023 Q4	$3.41M	Buy	+17,800	New	+$3.03M	﹤0.01%	1415
2023 Q2	–	Sell	-50	Closed	-$10K	–	3806
2023 Q1	$10K	Buy	+50	New	+$10.5K	﹤0.01%	3784
2017 Q2	–	Sell	-630	Closed	-$32K	–	4913
2017 Q1	$32K	Buy	+630	New	+$29.1K	﹤0.01%	4356
2015 Q1	–	Sell	-80	Closed	-$7K	–	5097
2014 Q4	$7K	Buy	+80	New	+$7.41K	﹤0.01%	5789
2014 Q3	–	Sell	-575	Closed	-$36K	–	5870
2014 Q2	$36K	Sell	575 -625	-52%	-$37.1K	﹤0.01%	5078
2014 Q1	$6K	Buy	1,200 +300	+33%	+$23.2K	﹤0.01%	5132
2013 Q4	$12K	Buy	+900	New	+$53.7K	﹤0.01%	4849
2013 Q3	–	Sell	-500	Closed	-$2K	–	5516
2013 Q2	$2K	Buy	+500	New	+$13.3K	﹤0.01%	5148

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank's ALNY Position: Q1 2026 in Review

Deutsche Bank increased its Alnylam Pharmaceuticals (ALNY) stake by 7% in Q1 2026, buying an estimated $16.8M and bringing the position to 761,464 shares worth $252M. The position accounts for 0.08% of the portfolio, ranked #231.

Deutsche Bank first reported a position in ALNY in Q2 2013 and has held it in 52 quarters since. The position peaked at $283M in Q4 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Deutsche Bank held 761,464 shares of Alnylam Pharmaceuticals worth $252M as of Q1 2026.
Deutsche Bank bought 49,489 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $16.8M.
Alnylam Pharmaceuticals made up 0.08% of Deutsche Bank's portfolio in Q1 2026, its #231 holding.
Deutsche Bank first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Deutsche Bank's Alnylam Pharmaceuticals position peaked at $283M in Q4 2025.
787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.